Consolidated Controlled Substances Regulations

Summary#

The federal government is proposing new Controlled Substances Regulations to replace and combine several existing rules (including the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations, and parts of the Food and Drug Regulations) into one modern set of rules. The proposal would harmonize authorizations and record‑keeping, formalize some temporary exemptions, let pharmacy technicians do more tasks, and let travellers carry up to a 90-day supply of prescribed controlled drugs; it is a proposal, and stakeholders have 60 days to comment.

What it does#

• Combines and modernizes multiple existing rules into the single Controlled Substances Regulations.
• Brings six existing class exemptions into the new regulations so those permissions are written into the rules rather than only existing as temporary exemptions.
• Harmonizes how different categories of drugs (narcotics, controlled drugs, targeted substances, restricted drugs) are handled.
• Pharmacy changes:
  • Allows pharmacy technicians to independently do many tasks now done only by pharmacists (compounding, transporting, delivering, destroying, transferring prescriptions), while pharmacists remain the only ones allowed to independently sell or provide controlled substances.
  • Lets pharmacists sell prescription controlled drugs to other pharmacists for routine “central fill” services (so a pharmacy can fill another pharmacy’s prescriptions without getting a dealer licence).
• Travel and personal possession:
  • Allows an individual to import or export up to a 90-day supply of a prescribed drug containing a controlled substance when entering or leaving Canada (currently 30-day limit for many such drugs).
• Licensed dealers and permits:
  • Keeps the dealer licensing scheme but changes reporting and permit details (e.g., monthly reports, more shipping details required on permit applications).
  • Requires reporting unexplained losses only to Health Canada (the police still must be notified of thefts).
• Research and test kits:
  • Simplifies the research authorization path for restricted drugs (moves away from a separate Part J process toward the existing exemption pathway used for other controlled substances).
  • Makes it easier to modify registered test kits (notification instead of full re‑registration) and allows some test kits to keep being sold even if their medical-device status changes.
• Administrative and enforcement updates:
  • Updates security and record‑keeping rules (e.g., fingerprinting services accredited for criminal record checks can be used).
  • Gives the Minister authority to share information with customs, the International Narcotics Control Board and foreign authorities, and to temporarily list substances as restricted drugs.
• Timing and process:
  • The proposal says the new regulations would come into force 365 days after final publication in the Canada Gazette, Part II to allow a transition period.

Who's affected#

• Health Canada (administration, inspections and training).
• Licensed dealers and importers/exporters of controlled substances.
• Pharmacists and pharmacy technicians (practice, record‑keeping, and central‑fill operations).
• Practitioners (doctors, dentists, veterinarians, nurse practitioners, midwives, podiatrists) — notably some limits on what nurse practitioners can prescribe would be removed.
• Hospitals (policies for storage, destruction and compounding).
• Researchers working with restricted drugs and institutions running clinical or lab studies.
• Holders of test‑kit registration numbers and businesses producing test kits.
• Individuals who travel with prescription medications containing controlled substances (they could carry larger quantities).
• Cannabis licence holders and businesses that handle drugs containing cannabis (some alignment changes are proposed).
• Small businesses — the government estimates most affected businesses are small; impacts are spread across many firms.

If anything above is unclear in the proposal, the source notes Health Canada will continue consultations, especially with pharmacy stakeholders and provinces/territories.

Why it matters#

• Simpler rules: Consolidating separate, overlapping regulations should make it easier for pharmacies, dealers, hospitals and inspectors to understand and follow the law. That can cut confusion and administrative time.
• Practical changes for patients and travellers: Letting people carry up to a 90-day supply of prescribed controlled medicines when travelling reduces the need to get temporary exemptions or extra prescriptions.
• Pharmacy workflow and access: Authorizing pharmacy technicians to do more, and enabling central‑fill services without a dealer licence, could speed dispensing and lower costs for pharmacies and patients.
• Research and public health: A single, clearer path for researchers working with restricted drugs could reduce paperwork for clinical research.
• Small net cost to government and businesses: Health Canada’s analysis estimates total present‑value benefits of $4.85 million and costs of $4.09 million over 10 years, for a net present‑value benefit of $0.76 million. Health Canada also expects implementation costs for outreach and inspector training that would be covered within existing budgets.
• Impacts are mixed at the business level: many small businesses are affected (about 19,774 estimated), but the average net cost per small business is small—about $119 present value over 10 years, and Health Canada estimates an overall small‑business net saving across the sector.

Remember: this is a proposed regulation. It is not law yet. The government is consulting and may change details before final rules are published.